Quantification of Respiratory-induced Prostate Motion

Prostate Cancer Clinical Trial

Official title:

Pilot Study on the Quantification of Respiratory-induced Prostate Motion During Radiation Therapy Using Continuous Real-time Tracking

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00980993
• Other study ID #: OHSU IRB00005606
• Status: Withdrawn
• Start date: September 2012
• Est. completion date: September 2014

Study information

• Verified date: October 2019
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Patient anatomy and position during the course of radiation therapy can vary from those used for treatment planning; a function of patient movement, uncertainty in positioning system, and organ motion. Traditionally, treatment margins are designed to compensate for interfraction prostate setup variability. This approach has the potential to lower the overall effectiveness of treatment because the prostate gland is a continuously moving target whose motion cannot be accurately accounted for solely on the basis of interfraction movement. More recently, the dosimetric relevance of intra-fraction prostate motion has been recognized, and may be compensated for by continuous real-time adaptive radiation therapy afforded by the Calypso 4D Localization System™. In the current study, the investigators propose to characterize intrafraction prostate motion. The investigators hypothesize that intrafraction prostate motion is correlated with respiratory motion.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2014
• Est. primary completion date: September 2013
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed stage I-III adenocarcinoma of the prostate gland

• Age > 18 years. Males of all races and ethnic groups

• Scheduled to receive radiation for definitive therapy

• Three (3) electromagnetic transponders implanted into prostate gland

Exclusion Criteria:

• Does not satisfy inclusion criteria

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Locations

Country	Name	City	State
United States	Oregon Health and Science University	Portland	Oregon

Sponsors (1)

Lead Sponsor	Collaborator
Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Motion amplitude	Measured at frequency of 10Hz	Continuously during radiation administration (generally 8 to 15 minutes in duration)

External Links

•   Department of Radiation Medicine, Oregon Health and Science University